Core D: Clinical Sciences
Core D: Clinical Sciences
批准号:
10457725
负责人:
JEFFREY M. JACOBSON
金额:
$42.05万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
未结题
起止时间:
1997-04-01 至 2027-04-30
关键词:
2019-nCoVAIDS clinical trial groupAIDS preventionAIDS/HIV problemAcquired Immunodeficiency SyndromeAddressAmericanAncillary StudyAreaAwardBiologicalBiological Specimen BanksBiometryBiostatistics CoreBronchoalveolar Lavage FluidCaringCerebrospinal FluidCervicalClinicalClinical DataClinical InvestigatorClinical ResearchClinical SciencesClinical ServicesCohort StudiesCollaborationsCommunitiesDataDatabasesDevelopmentEnrollmentEnsureEpidemicFecesFosteringGender IssuesGenitalGenitaliaGoalsGrantHIVHepatitis C virusHumanHuman Subject ResearchIndividualInstitutionInstitutional Review BoardsInternationalLaboratoriesLinkLungMentorsMentorshipMycobacterium tuberculosisParticipantPathogenesisPatient CarePatientsPennsylvaniaPersonsPlacentaPopulationPreventionProtocols documentationProviderResearchResearch DesignResearch PersonnelResearch Project GrantsResourcesRiskSamplingServicesSiteSpecimenSubstance Use DisorderSystemSystems BiologyTissuesTranslational ResearchUgandaUmbilical Cord BloodUnited States National Institutes of HealthUniversitiesViral PathogenesisWorkcis-femaleclinical data repositoryco-infectioncohortdata repositorydesignexperiencegastrointestinalgenital secretionimplementation scienceinfection riskinterestinvestigator trainingmeetingsmenperipheral bloodrectalrepositoryresearch studyservice organizationsexsubstance usesuccesstransgender womentranslational scientisttranslational studyworking group
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT – CLINICAL SCIENCES CORE D
The RUSTBELT CFAR Clinical Sciences Core D, managed by an integrated group of highly experienced
HIV/AIDS clinical investigators and staff, will serve as the centralized resource for CFAR users proposing or
conducting clinical or translational research involving human participants, clinical data, or samples. The primary
services provided by the core are (i) rapid access to existing clinical data and repository samples from persons
with HIV (PWH), (ii) on-demand acquisition of fresh biologic samples from PWH, persons at risk for infection,
and uninfected low risk individuals, and (iii) centralized clinical support provided by the CFAR to investigators for the
design, implementation, conduct, and analysis of clinical research studies across the sites in the expanded
RUSTBELT CFAR. In this next grant cycle, our capabilities will be dramatically enhanced by the addition of the
outstanding Pittsburgh clinical cohorts. The merged Core will include expertise in HIV prevention, substance
use, and cure research. Furthermore, the range of specimens that can be obtained will also be dramatically
enhanced through the procurement of leukopheresis samples, gastrointestinal tissue, cerebrospinal fluid (CSF),
cervical tissue, placenta, cord blood, bronchoalveolar lavage fluid (BAL), stool, and genital secretions for
translational research. Core D maintains strong relationships with patient communities and affiliated AIDS
service organizations and agencies through regular meetings of the Community Advisory Boards (CABs) and
ongoing initiatives including AIDS-free Pittsburgh and End the Epidemic in Cleveland (EtHE in CLE). RUSTBELT
CFAR Core D leaders will guide and link CFAR investigators to ongoing cohorts and study groups such as the
Pittsburgh HIV Lung Research Cohort and the CFAR Network of Integrated Clinical Systems to enhance
utilization of these powerful existing resources. Core D will also work closely with the Developmental Core B
to ensure success of the projects selected for pilot and catalytic awards. Additionally, Core D will collaborate
closely with Cores E (Viral Pathogenesis & Persistence) and F (Systems Biology & Biostatistics) to ensure
that CFAR users are provided with the full spectrum of available resources in an efficient and coordinated
fashion. Finally, Core D will collaborate with the Uganda Core C to provide CFAR users access to participant
data and samples from the CFAR international site in Uganda, as well as to link international CFAR investigators
to resources available from Core D. Thus, Core D broadens utilization of existing resources with users from
multiple institutions and engages new and/or young investigators in HIV/AIDS research at the local, national,
and international levels.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Innate and adaptive defenses against SARS-COV-2 in the oral cavity during acute unvaccinated and breakthrough infections
-
批准号:10667248
-
项目类别:
-
资助金额:$48.3万
-
财政年份:2022
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
Long-acting, self-administered HIV therapy with th CCR5 antibody PRO 140
-
批准号:8541374
-
项目类别:
-
资助金额:$302.63万
-
财政年份:2011
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
Long-acting, self-administered HIV therapy with th CCR5 antibody PRO 140
-
批准号:8546145
-
项目类别:
-
资助金额:$260.03万
-
财政年份:2011
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
Long-Acting HIV Therapy for Injection Drug Users
-
批准号:8215745
-
项目类别:
-
资助金额:$69.91万
-
财政年份:2010
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
Long-Acting HIV Therapy for Injection Drug Users
-
批准号:9178399
-
项目类别:
-
资助金额:$55.71万
-
财政年份:2010
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
Long-Acting HIV Therapy for Injection Drug Users
-
批准号:8425102
-
项目类别:
-
资助金额:$64.5万
-
财政年份:2010
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
Long-Acting HIV Therapy for Injection Drug Users
-
批准号:8603231
-
项目类别:
-
资助金额:$6.32万
-
财政年份:2010
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
Long-Acting HIV Therapy for Injection Drug Users
-
批准号:8054808
-
项目类别:
-
资助金额:$71.58万
-
财政年份:2010
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
HIV Entry Inhibitor Therapy with the CCR5 mAb PRO 140
-
批准号:7575211
-
项目类别:
-
资助金额:$40.24万
-
财政年份:2008
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
Case Clinical Trials Unit
-
批准号:10532725
-
项目类别:
-
资助金额:$243.64万
-
财政年份:2007
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
Case Clinical Trials Unit
-
批准号:10057995
-
项目类别:
-
资助金额:$257.57万
-
财政年份:2007
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
Case Clinical Trials Unit
-
批准号:10305665
-
项目类别:
-
资助金额:$258.27万
-
财政年份:2007
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
HIV Entry Inhibitor Therapy with the CCR5 mAb PRO 140
-
批准号:6998059
-
项目类别:
-
资助金额:$31.15万
-
财政年份:2006
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
Core D: Clinical Sciences
-
批准号:10615816
-
项目类别:
-
资助金额:$40.81万
-
财政年份:1997
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
ADULT AIDS CLINICAL TRIALS UNIT
-
批准号:6434508
-
项目类别:
-
资助金额:$28.68万
-
财政年份:1986
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
ADULT AIDS CLINICAL TRIALS UNIT
-
批准号:6259839
-
项目类别:
-
资助金额:$73.03万
-
财政年份:1986
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
Sphingolipids as a Novel Therapy for Radiation Lung Injury
-
批准号:8114298
-
项目类别:
-
资助金额:$40.72万
-
财政年份:--
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
HIV Entry Inhibitor Therapy with the CCR5 mAb PRO 140
-
批准号:7394490
-
项目类别:
-
资助金额:$39.41万
-
财政年份:--
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
HIV Entry Inhibitor Therapy with the CCR5 mAb PRO 140
-
批准号:7310366
-
项目类别:
-
资助金额:$69.25万
-
财政年份:--
-
负责人:JEFFREY M. JACOBSON
-
依托单位:
海外基金